[go: up one dir, main page]

CA2337964A1 - Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique - Google Patents

Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique Download PDF

Info

Publication number
CA2337964A1
CA2337964A1 CA002337964A CA2337964A CA2337964A1 CA 2337964 A1 CA2337964 A1 CA 2337964A1 CA 002337964 A CA002337964 A CA 002337964A CA 2337964 A CA2337964 A CA 2337964A CA 2337964 A1 CA2337964 A1 CA 2337964A1
Authority
CA
Canada
Prior art keywords
egf
polypeptide
injury
growth factor
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002337964A
Other languages
English (en)
Inventor
Seth P. Finklestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2337964A1 publication Critical patent/CA2337964A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédés de prévention, de réduction ou d'élimination d'un déficit neurologique provoqué par une lésion du système nerveux central (SNC). Les procédés peuvent être mis en oeuvre, par exemple, au moyen de l'administration d'un polypeptide faisant partie de la famille du facteur de croissance épidermique (EGF) à un patient atteint d'un tel déficit.
CA002337964A 1998-08-07 1999-08-06 Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique Abandoned CA2337964A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9583098P 1998-08-07 1998-08-07
US60/095,830 1998-08-07
PCT/US1999/018022 WO2000007611A1 (fr) 1998-08-07 1999-08-06 Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique

Publications (1)

Publication Number Publication Date
CA2337964A1 true CA2337964A1 (fr) 2000-02-17

Family

ID=22253781

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002337964A Abandoned CA2337964A1 (fr) 1998-08-07 1999-08-06 Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique

Country Status (4)

Country Link
EP (1) EP1100523A4 (fr)
JP (1) JP2002522394A (fr)
CA (1) CA2337964A1 (fr)
WO (1) WO2000007611A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472375B1 (fr) 2002-01-08 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Produits geniques a expression differenciee dans des cellules cancereuses du sein et methodes d'utilisation associees
EP1449538A1 (fr) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de TACE ou amphirégulin pour moduler la transactivation de signaux récepteur EGF
CA2942172A1 (fr) * 2014-03-06 2015-09-11 Children's National Medical Center Traitement de lesion cerebrale neonatale avec hb-egf

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502538A (ja) * 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン

Also Published As

Publication number Publication date
EP1100523A1 (fr) 2001-05-23
JP2002522394A (ja) 2002-07-23
EP1100523A4 (fr) 2005-02-02
WO2000007611A1 (fr) 2000-02-17

Similar Documents

Publication Publication Date Title
JP4847634B2 (ja) 中枢神経系の虚血または外傷の機能的回復を増大させる方法
US20110251267A1 (en) Methods of using polynucleotides encoding truncated glial cell line-derived neurotrophic factor
IE912793A1 (en) Chimeric neurotrophic factors
JP2003159083A (ja) 新規な神経栄養因子
JP2001513334A (ja) ヘパリン結合増殖因子（ｈｂｇｆ）ポリペプチド
US20110262432A1 (en) mutated netrin 4 proteins, fragments thereof and their uses as drugs
US20100247520A1 (en) Mutated netrin 4, fragments thereof and uses thereof as drugs
US6171584B1 (en) Method of treatment with growth/differentiation factors of the TGF-β family
CA2337964A1 (fr) Traitement de l'ischemie ou du traumatisme du systeme nerveux central avec des polypeptides du type facteur de croissance epidermique
CA2216165C (fr) Peptides ndf (facteur de differenciation neu)
US20050220794A1 (en) Growth/differentiation factor of the TGF-beta family
US6080845A (en) Monoclonal antibody against utricular epithelium
Stortelers The role of EGF-like growth factors in selective ErbB receptor dimerisation

Legal Events

Date Code Title Description
FZDE Dead